CurrentKaiser PermanentePolicy 03-33

Meniett low-pressure pulse generator (transtympanic micropressure therapy) for Meniere's disease

Defines indications, contraindications, and utilization management criteria for use of the Meniett low-pressure pulse generator (transtympanic micropressure therapy) for patients with Meniere's disease in the Kaiser Permanente Georgia region.

Policy Summary

PayerKaiser Permanente

PolicyMeniett low-pressure pulse generator (transtympanic micropressure therapy) for Meniere's disease

Policy CodePolicy 03-33

Change TypeReviewed/Revised

Effective DateDec 12, 2008

Next Review Date

Key ActionDocument an adequate trial of standard therapy and include a letter of necessity from the treating ENT when requesting authorization for the Meniett device.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

H81.09Listed diagnosis code

E2120, A4638Listed indicators

AgainstRecommendation

Letter requiredDocumentation

Coverage Criteria & Recommendation

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Covered with criteria / Recommendation stance

Covered only when ALL of the following are met (policy otherwise recommends against):

Entry criteria: 1) Diagnosis of severe Meniere's disease (ICD-10 H81.09). 2) No significant improvement after an adequate trial of standard (conventional) therapy (for example: low-sodium diet, diuretics, stress management). 3) A letter of necessity from the treating ENT physician documenting the indication. 4) Documentation that an adequate trial of conservative therapy was attempted; note that an inadequate trial of standard therapy is a contraindication.

Policy issues a recommendation against positive pressure therapy based on systematic review and randomized trials showing lack of effectiveness, but allows consideration in rare difficult cases with documentation of failure of standard therapy.

The policy considers transtympanic positive pressure therapy for Meniere's disease to be experimental/investigational in general. The document lists lack of an adequate trial of standard therapy as a contraindication and states that, except for rare difficult cases, clinicians should not prescribe positive pressure therapy for Meniere's disease.

The policy issues a recommendation against positive pressure therapy (for example, the Meniett device) based on a Cochrane systematic review and two randomized trials that showed no benefit. The policy characterizes the aggregate evidence as Grade B with high confidence and concludes the preponderance of benefit favors not using these devices, while noting rare patients with limited options may be considered individually.

Prior Authorization, Documentation, and Provider Requirements

Prior Authorization

Prior authorization / documentation required for Meniett (E2120, A4638)

Use of the Meniett device (indicators E2120, A4638) requires documentation that the indication is severe Meniere's disease, that there has been no significant improvement with standard therapy, and a treating ENT letter of necessity; prior authorization is implied by utilization management review.

Indicators listed: E2120, A4638
Documentation must show severe Meniere's disease and lack of improvement with standard therapy
Treating ENT letter of necessity is required

Step Therapy

Document adequate trial of conservative therapy first

An adequate trial of standard (conventional) therapy must be documented before considering the Meniett device; standard therapy includes low-sodium diet, diuretics, and stress management and there must be no significant improvement with these measures.

Document trial and lack of significant improvement with low-sodium diet
Document trial and lack of significant improvement with diuretics
Document trial and lack of significant improvement with stress management

Documentation Required

Treating ENT letter of necessity required

A letter of medical necessity from the treating ENT physician is required to support use of the Meniett device.

Letter must state diagnosis of severe Meniere's disease and prior therapies tried
Letter should accompany prior authorization/claim documentation

Denial Risk

Denial triggers: inadequate trial or investigational status

Claims may be denied if documentation shows an inadequate trial of standard therapy or if the treatment is considered investigational; the policy issues a recommendation against positive pressure therapy based on evidence of ineffectiveness.

Denial risk if inadequate documentation of conservative therapy trial
Denial risk because policy recommends against positive pressure therapy due to lack of demonstrated benefit

Clinical Background

Meniere's disease is an inner-ear disorder characterized by episodic vertigo, tinnitus, aural fullness, and fluctuating hearing loss. Many patients improve over time while a subset have persistent or progressive symptoms; the Meniett device delivers low‑amplitude pressure pulses to the middle ear via a tympanostomy tube and has been proposed as a non‑destructive alternative for patients who fail conventional medical therapy.

Device Definition

Meniett device / transtympanic micropressure therapy — definition

Device descriptionHand-held low-pressure pulse generator that transmits low-frequency, low-amplitude pressure pulses to the middle ear through an implanted ventilation (tympanostomy) tube; FDA approved in December 1999.

Delivery methodPressure pulses transmitted via tubing and an earplug into the middle ear after insertion of a small ventilation tube into the eardrum (outpatient procedure).

Intended effectTheoretical evacuation of inner ear (endolymph) fluid to reduce vertigo, tinnitus, aural fullness, and fluctuating hearing loss in Meniere's disease patients who failed medical therapy.

Patient useSmall, portable device intended for patient self-administration: typical regimen five minutes, three times per day while symptoms last (often for two or more weeks).

Clinical contextPromoted as a noninvasive, conservative option for patients who have failed standard medical therapy (low-sodium diet, diuretics, stress management).